Foghorn gets $300M plus investment from Lilly under cancer drug partnership

Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, was bearing fruit.